Anti-hypertensive medications and erectile dysfunction: focus on β-blockers
Endocrine · 13.09.2024 · 87 (1) · 11-26
DOI: 10.1007/s12020-024-04020-x ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Endocrine, online erschienen am 13.09.2024. Verfasst von G Corona und 6 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Unit, Maggiore Hospital, Azienda-Usl Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Erectile Dysfunction, Antihypertensive Agents, Adrenergic beta-Antagonists, Hypertension. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Recovery and Resilience Plan, Investment PE8 - Project Age-It: "Ageing Well in an Ageing Society, Recovery and Resilience Plan, Investment PE8 – Project Age-It: “Ageing Well in an Ageing Society.
Abstract (Originalsprache)
Purpose
Although anti-hypertensive medications, including thiazides and β-blockers (BBs) in particular, have been suggested to cause erectile dysfunction (ED) their real contribution is still conflicting. The aim of this paper is to summarize available evidence providing an evidence-based critical analysis of the topic.
Methods
An overall comprehensive narrative review was performed using Medline, Embase and Cochrane search. In addition, to better understand the impact of BBs on ED a specific systematic review was also performed.
Results
The negative role of centrally acting drugs, such as clonidine and α-methyldopa, is well documented althuogh limited controlled trials are available. Angiotensin-converting enzyme inhibitors (ACEis), angiotensin receptor blockers (ARBs), and calcium-channel-blockers (CCBs) have neutral (CCBs) or even positive (ACEis and ARBs) effects on erectile function. Despite some preliminary negative reports, more recent evidence does not confirm the negative impact of thiazides. BBs should be still considered the class of medications more often associated with ED, although better outcomes can be drawn with nebivolol.
Conclusion
Sexual function should be assessed in all patients with arterial hypertension, either at diagnosis or after the prescription of specific medications. A close related patient-physician interaction and discussion can overcome possible negative outcomes allowing a successful management of possible side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology Unit, Maggiore Hospital, Azienda-Usl Bologna, Bologna, Italy.
- Department of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy.
- Diabetes Center, Humanitas Gavezzani Institute, Bergami, Italy.
- Unit of Endocrinology, Diabetology and Medical Andrology, IRCSS, Humanitas Research Hospital, Rozzano, Milan, Italy.
- Endocrinology Clinic, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.
- Endocrinology Unit Department of Experimental, Clinical and Biomedical Sciences, University of Florence, Florence, Italy.
Förderung
- Recovery and Resilience Plan, Investment PE8 - Project Age-It: "Ageing Well in an Ageing Society
- Recovery and Resilience Plan, Investment PE8 – Project Age-It: “Ageing Well in an Ageing Society
Zitieren
APA
Corona, G., Vena, W., Pizzocaro, A., Salvio, G., Sparano, C., Sforza, A., & Maggi, M. (2024). Anti-hypertensive medications and erectile dysfunction: focus on β-blockers. Endocrine, 87(1), 11-26. https://doi.org/10.1007/s12020-024-04020-x
Vancouver
Corona G, Vena W, Pizzocaro A, Salvio G, Sparano C, Sforza A, et al. Anti-hypertensive medications and erectile dysfunction: focus on β-blockers. Endocrine. 2024;87(1):11-26. doi:10.1007/s12020-024-04020-x
BibTeX
@article{Corona2024,
author = {Corona, G and Vena, W and Pizzocaro, A and Salvio, G and Sparano, C and Sforza, A and Maggi, M},
title = {Anti-hypertensive medications and erectile dysfunction: focus on β-blockers},
journal = {Endocrine},
year = {2024},
volume = {87},
number = {1},
pages = {11--26},
doi = {10.1007/s12020-024-04020-x}
}
EUVIMED